Finnish Nightingale Health receives €20m EIB loan

The investment is backed by the Investment Plan for Europe, or Juncker Plan.

Photo: EPA EU Commissioner in charge of Jobs, Growth, Investment and Competitiveness Jyrki Katainen

The Investment Plan for Europe, or Juncker Plan, is reportedly backing a €20m European Investment Bank (EIB) loan to Finnish company Nightingale Health. The company will use the financing to further develop its blood analysis technology, which facilitates the detection and prevention of chronic diseases.

"We are delighted that the Investment Plan for Europe is fostering the development of Nightingale's technology which has the potential to add significant value to European healthcare," Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, who attended the signature event in Helsinki, said.

He also stressed that Nightingale's innovative blood analysis technology can detect early signs of chronic diseases, improving for example the assessment of a person's future risk of developing heart disease or type 2 diabetes. This could "reap huge benefits" in EU's healthcare and can strengthen "Europe's position today as a world leader in cutting edge medical research."

Similar articles